Global Renal Biomarker Market Research and Forecast 2018-2023
Kidney diseases or renal diseases is one of the major causes of deaths across the globe. The incidence of the renal diseases, particularly in geriatric population is rising rapidly owing to better life expectancy due to improvements in medical systems. Diabetes and high blood pressure are the leading cause of renal disease. A biomarker is an indicator of a specific biological state, relevant to the risk for, the presence of, or the stage of any disease. Biomarkers are clinically used for various purpose such as screening, diagnosing, or monitoring the activity of any diseases. in addition, it can guide molecularly targeted therapy or assess therapeutic response. Research and development activities undertaken by the biomarker manufacturers have led to identification of novel renal biomarkers for delivering better diagnostic accuracy and for improving patient outcomes.
Major factors contributing to the growth of the global renal biomarker market include innovation in the biomarker for improving lives of the people with kidney diseases. In addition, increasing diabetic patient pool and rising number of patients with high blood pressure coupled with aging population as well as increasing prevalence of various kidney related disease are also contributing significantly in the growth of renal biomarker market. However, lack of regulatory and reimbursement systems, and limited market capabilities in the under-developed markets hinders the growth of the market.
The renal biomarker market can be segmented on the basis of, type, diagnostic technique and end users. Based on the type, the renal biomarker market is bifurcated as diagnostic biomarkers, prognostic biomarkers, predictive biomarkers, and pharmacodynamic biomarkers. On the basis of diagnostic technique, the market is diversified as ELISA, colorimetric assay, liquid chromatography – mass spectrometry and particle enhanced turbidimetric immunoassay. Based on the end users, the renal biomarker market is sub-divided as hospitals, diagnostic labs and research centers. Among the diagnostic technique, ELISA is expected to hold the largest market share. In addition, diagnostic labs among the end users is projected to be dominating segment.
The global renal biomarker market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The North America is expected to be dominating in the renal biomarker market owing to the presence of high quality healthcare infrastructure. In addition, prevalence rate of renal diseases is high in this region. Europe is another significant market and holds a considerable market share in the global renal biomarker market.
Some of the key players operating in the global renal biomarker market are Abbott Laboratories Inc., Astute Medical Inc., Beckman Coulter Inc., Novartis AG, Roche Diagnostics and several others. In order to sustain in the competitive market, these players adopt various strategies such as merger & acquisitions, expansions, joint ventures and product development and partnership and collaboration. For instance, Bristol-Myers Squibb in January 2017 along with the GeneCentric Diagnostics entered into a Biomarker Research Collaboration. The collaboration is to explore if the Cancer Subtype Platform (CSP) of the GeneCentric is capable of identifying translational biomarkers for Opdivo. OPDIVO (nivolumab) is used as an indication for the treatment of advanced renal cell carcinoma (RCC) patients who have received prior anti-angiogenic therapy.
RESEARCH METHODOLOGY
The market study of renal biomarker market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases such as American College of Rheumatology, American Association for Clinical Chemistry (AACC), and American Autoimmune Related Diseases Association (AARDA), among others.
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue
Supplier Websites such as Alibaba, amazon for pricing analysis
The report is intended for drug manufacturers, healthcare provider, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.
MARKET SEGMENTATION:
Global Renal biomarker market is segmented on the basis of regional outlook and following segments:
Global Renal biomarker Market Research and Analysis, By Type
Global Renal biomarker Market Research and Analysis, By Diagnostic Technique
Global Renal biomarker Market Research and Analysis, By End Users
Global Renal biomarker Market Research and Analysis, By Region
THE REPORT COVERS:
Comprehensive research methodology of global renal biomarker market.
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global renal biomarker market.
Insights about market determinants which are stimulating the global renal biomarker market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
Major factors contributing to the growth of the global renal biomarker market include innovation in the biomarker for improving lives of the people with kidney diseases. In addition, increasing diabetic patient pool and rising number of patients with high blood pressure coupled with aging population as well as increasing prevalence of various kidney related disease are also contributing significantly in the growth of renal biomarker market. However, lack of regulatory and reimbursement systems, and limited market capabilities in the under-developed markets hinders the growth of the market.
The renal biomarker market can be segmented on the basis of, type, diagnostic technique and end users. Based on the type, the renal biomarker market is bifurcated as diagnostic biomarkers, prognostic biomarkers, predictive biomarkers, and pharmacodynamic biomarkers. On the basis of diagnostic technique, the market is diversified as ELISA, colorimetric assay, liquid chromatography – mass spectrometry and particle enhanced turbidimetric immunoassay. Based on the end users, the renal biomarker market is sub-divided as hospitals, diagnostic labs and research centers. Among the diagnostic technique, ELISA is expected to hold the largest market share. In addition, diagnostic labs among the end users is projected to be dominating segment.
The global renal biomarker market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The North America is expected to be dominating in the renal biomarker market owing to the presence of high quality healthcare infrastructure. In addition, prevalence rate of renal diseases is high in this region. Europe is another significant market and holds a considerable market share in the global renal biomarker market.
Some of the key players operating in the global renal biomarker market are Abbott Laboratories Inc., Astute Medical Inc., Beckman Coulter Inc., Novartis AG, Roche Diagnostics and several others. In order to sustain in the competitive market, these players adopt various strategies such as merger & acquisitions, expansions, joint ventures and product development and partnership and collaboration. For instance, Bristol-Myers Squibb in January 2017 along with the GeneCentric Diagnostics entered into a Biomarker Research Collaboration. The collaboration is to explore if the Cancer Subtype Platform (CSP) of the GeneCentric is capable of identifying translational biomarkers for Opdivo. OPDIVO (nivolumab) is used as an indication for the treatment of advanced renal cell carcinoma (RCC) patients who have received prior anti-angiogenic therapy.
RESEARCH METHODOLOGY
The market study of renal biomarker market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases such as American College of Rheumatology, American Association for Clinical Chemistry (AACC), and American Autoimmune Related Diseases Association (AARDA), among others.
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue
Supplier Websites such as Alibaba, amazon for pricing analysis
The report is intended for drug manufacturers, healthcare provider, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.
MARKET SEGMENTATION:
Global Renal biomarker market is segmented on the basis of regional outlook and following segments:
Global Renal biomarker Market Research and Analysis, By Type
Global Renal biomarker Market Research and Analysis, By Diagnostic Technique
Global Renal biomarker Market Research and Analysis, By End Users
Global Renal biomarker Market Research and Analysis, By Region
THE REPORT COVERS:
Comprehensive research methodology of global renal biomarker market.
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global renal biomarker market.
Insights about market determinants which are stimulating the global renal biomarker market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
CHAPTER 1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. MARKET DEFINITION
2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. RULES & REGULATIONS
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. JAPAN
2.3.1.5. INDIA
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISING PREVALENCE OF VARIOUS KIDNEY RELATED DISEASES
3.1.2. SPARKING INNOVATION TO IMPROVE THE LIVES OF PEOPLE WITH KIDNEY DISEASE
3.1.3. HIGH POPULATION POOL OF DIABETES AND BLOOD PRESSURE- LEADING CAUSE OF RENAL DISEASE
3.1.4. KIDNEY INJURY BIOMARKERS: VALUE IN DRUG DEVELOPMENT
3.1.5. AWARENESS PROGRAMMES FOR ACUTE KIDNEY INJURY(AKI)
3.2. RESTRAINTS
3.2.1. LACK OF REGULATORY & REIMBURSEMENT SYSTEMS
3.2.2. LIMITED MARKET CAPABILITIES IN UNDERDEVELOPED MARKETS
3.3. OPPORTUNITIES
3.3.1. GROWING TREND TOWARDS PERSONALIZED MEDICINE
3.3.2. RISING DEMAND FROM EMERGING ECONOMIES
CHAPTER 4. MARKET SEGMENTATION
4.1. GLOBAL RENAL BIOMARKER MARKET, BY TYPE
4.1.1. DIAGNOSTIC BIOMARKERS
4.1.2. PROGNOSTIC BIOMARKERS
4.1.3. PREDICTIVE BIOMARKERS
4.1.4. PHARMACODYNAMIC BIOMARKERS
4.2. GLOBAL RENAL BIOMARKER MARKET, BY DIAGNOSTIC TECHNIQUE
4.2.1. ELISA
4.2.2. COLORIMETRIC ASSAY
4.2.3. LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
4.2.4. PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY
4.3. GLOBAL RENAL BIOMARKER BY END USERS
4.3.1. HOSPITALS
4.3.2. DIAGNOSTIC LABS
4.3.3. RESEARCH CENTRES
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. KEY COMPANY ANALYSIS
5.2. KEY STRATEGY ANALYSIS
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. U.K
6.2.2. GERMANY
6.2.3. ITALY
6.2.4. SPAIN
6.2.5. FRANCE
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. TAIWAN
6.3.4. JAPAN
6.3.5. ROAPAC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.2. ASTELLAS PHARMA INC.
7.3. ASTUTE MEDICAL, INC.
7.4. BAYER AG
7.5. BECKMAN COULTER INC.
7.6. BIO PREVENTIVE MEDICINE CORP.
7.7. BIOMÉRIEUX SA
7.8. BIOPORTO A/S
7.9. ENZO LIFE SCIENCES, INC.
7.10. EVOTEC A.G.
7.11. MYRIAD GENETICS INC.
7.12. NOVARTIS AG
7.13. PACIFIC BIOMARKERS
7.14. PLATO BIO PHARMA INC.
7.15. PLIANT THERAPEUTICS, INC.
7.16. R & D SYSTEMS
7.17. RANDOX LABORATORIES LTD.
7.18. ROCHE DIAGNOSTICS
7.19. SIEMENS AG
7.20. THERMO FISHER SCIENTIFIC INC.
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. MARKET DEFINITION
2.2. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. RULES & REGULATIONS
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. JAPAN
2.3.1.5. INDIA
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISING PREVALENCE OF VARIOUS KIDNEY RELATED DISEASES
3.1.2. SPARKING INNOVATION TO IMPROVE THE LIVES OF PEOPLE WITH KIDNEY DISEASE
3.1.3. HIGH POPULATION POOL OF DIABETES AND BLOOD PRESSURE- LEADING CAUSE OF RENAL DISEASE
3.1.4. KIDNEY INJURY BIOMARKERS: VALUE IN DRUG DEVELOPMENT
3.1.5. AWARENESS PROGRAMMES FOR ACUTE KIDNEY INJURY(AKI)
3.2. RESTRAINTS
3.2.1. LACK OF REGULATORY & REIMBURSEMENT SYSTEMS
3.2.2. LIMITED MARKET CAPABILITIES IN UNDERDEVELOPED MARKETS
3.3. OPPORTUNITIES
3.3.1. GROWING TREND TOWARDS PERSONALIZED MEDICINE
3.3.2. RISING DEMAND FROM EMERGING ECONOMIES
CHAPTER 4. MARKET SEGMENTATION
4.1. GLOBAL RENAL BIOMARKER MARKET, BY TYPE
4.1.1. DIAGNOSTIC BIOMARKERS
4.1.2. PROGNOSTIC BIOMARKERS
4.1.3. PREDICTIVE BIOMARKERS
4.1.4. PHARMACODYNAMIC BIOMARKERS
4.2. GLOBAL RENAL BIOMARKER MARKET, BY DIAGNOSTIC TECHNIQUE
4.2.1. ELISA
4.2.2. COLORIMETRIC ASSAY
4.2.3. LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
4.2.4. PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY
4.3. GLOBAL RENAL BIOMARKER BY END USERS
4.3.1. HOSPITALS
4.3.2. DIAGNOSTIC LABS
4.3.3. RESEARCH CENTRES
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. KEY COMPANY ANALYSIS
5.2. KEY STRATEGY ANALYSIS
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. U.K
6.2.2. GERMANY
6.2.3. ITALY
6.2.4. SPAIN
6.2.5. FRANCE
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. TAIWAN
6.3.4. JAPAN
6.3.5. ROAPAC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.2. ASTELLAS PHARMA INC.
7.3. ASTUTE MEDICAL, INC.
7.4. BAYER AG
7.5. BECKMAN COULTER INC.
7.6. BIO PREVENTIVE MEDICINE CORP.
7.7. BIOMÉRIEUX SA
7.8. BIOPORTO A/S
7.9. ENZO LIFE SCIENCES, INC.
7.10. EVOTEC A.G.
7.11. MYRIAD GENETICS INC.
7.12. NOVARTIS AG
7.13. PACIFIC BIOMARKERS
7.14. PLATO BIO PHARMA INC.
7.15. PLIANT THERAPEUTICS, INC.
7.16. R & D SYSTEMS
7.17. RANDOX LABORATORIES LTD.
7.18. ROCHE DIAGNOSTICS
7.19. SIEMENS AG
7.20. THERMO FISHER SCIENTIFIC INC.
LIST OF TABLES
TABLE 1 GLOBAL RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 2 GLOBAL DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 3 GLOBAL PROGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 4 GLOBAL PREDICTIVE BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 5 GLOBAL PHARMACODYNAMIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 6 GLOBAL RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 7 GLOBAL ELISA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 8 GLOBAL COLORIMETRIC ASSAY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 9 GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 10 GLOBAL PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 11 GLOBAL RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 12 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 13 GLOBAL DIAGNOSTIC LABS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 14 GLOBAL RESEARCH CENTRES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 15 NORTH AMERICAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 16 NORTH AMERICAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 17 NORTH AMERICAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 18 NORTH AMERICAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 19 EUROPEAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 20 EUROPEAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 21 EUROPEAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 22 EUROPEAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 23 APAC RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 24 APAC RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 25 APAC RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 26 APAC RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 27 ROW RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 28 ROW RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 29 ROW RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 1 GLOBAL RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 2 GLOBAL DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 3 GLOBAL PROGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 4 GLOBAL PREDICTIVE BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 5 GLOBAL PHARMACODYNAMIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 6 GLOBAL RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 7 GLOBAL ELISA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 8 GLOBAL COLORIMETRIC ASSAY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 9 GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 10 GLOBAL PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 11 GLOBAL RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 12 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 13 GLOBAL DIAGNOSTIC LABS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 14 GLOBAL RESEARCH CENTRES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 15 NORTH AMERICAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 16 NORTH AMERICAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 17 NORTH AMERICAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 18 NORTH AMERICAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 19 EUROPEAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 20 EUROPEAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 21 EUROPEAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 22 EUROPEAN RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 23 APAC RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 24 APAC RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 25 APAC RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 26 APAC RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 27 ROW RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
TABLE 28 ROW RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 29 ROW RENAL BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL RENAL BIOMARKER MARKET SHARE BY TYPE, 2017 VS 2023 (%)
FIGURE 2 GLOBAL RENAL BIOMARKER MARKET SHARE BY DIAGNOSTIC TECHNIQUE, 2017 VS 2023 (%)
FIGURE 3 GLOBAL RENAL BIOMARKER MARKET SHARE BY END USERS, 2017 VS 2023 (%)
FIGURE 4 US RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 5 CANADA RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 6 UK RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 7 FRANCE RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 8 GERMANY RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 9 ITALY RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 10 SPAIN RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 11 ROE RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 12 INDIA RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 13 CHINA RENAL BIOMARKER MARKETSIZE, 2017-2023 ($ MILLION)
FIGURE 14 TAIWAN RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 15 JAPAN RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 16 ROAPAC RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 17 REST OF THE WORLD RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
1. ABBOTT LABORATORIES
2. ASTELLAS PHARMA INC.
3. ASTUTE MEDICAL, INC.
4. BAYER AG
5. BECKMAN COULTER INC.
6. BIO PREVENTIVE MEDICINE CORP.
7. BIOMÉRIEUX SA
8. BIOPORTO A/S
9. ENZO LIFE SCIENCES, INC.
10. EVOTEC A.G.
11. MYRIAD GENETICS INC.
12. NOVARTIS AG
13. PACIFIC BIOMARKERS
14. PLATO BIO PHARMA INC.
15. PLIANT THERAPEUTICS, INC.
16. R & D SYSTEMS
17 RANDOX LABORATORIES LTD.
18. ROCHE DIAGNOSTICS
19. SIEMENS AG
20. THERMO FISHER SCIENTIFIC INC.
FIGURE 1 GLOBAL RENAL BIOMARKER MARKET SHARE BY TYPE, 2017 VS 2023 (%)
FIGURE 2 GLOBAL RENAL BIOMARKER MARKET SHARE BY DIAGNOSTIC TECHNIQUE, 2017 VS 2023 (%)
FIGURE 3 GLOBAL RENAL BIOMARKER MARKET SHARE BY END USERS, 2017 VS 2023 (%)
FIGURE 4 US RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 5 CANADA RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 6 UK RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 7 FRANCE RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 8 GERMANY RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 9 ITALY RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 10 SPAIN RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 11 ROE RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 12 INDIA RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 13 CHINA RENAL BIOMARKER MARKETSIZE, 2017-2023 ($ MILLION)
FIGURE 14 TAIWAN RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 15 JAPAN RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 16 ROAPAC RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 17 REST OF THE WORLD RENAL BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
1. ABBOTT LABORATORIES
2. ASTELLAS PHARMA INC.
3. ASTUTE MEDICAL, INC.
4. BAYER AG
5. BECKMAN COULTER INC.
6. BIO PREVENTIVE MEDICINE CORP.
7. BIOMÉRIEUX SA
8. BIOPORTO A/S
9. ENZO LIFE SCIENCES, INC.
10. EVOTEC A.G.
11. MYRIAD GENETICS INC.
12. NOVARTIS AG
13. PACIFIC BIOMARKERS
14. PLATO BIO PHARMA INC.
15. PLIANT THERAPEUTICS, INC.
16. R & D SYSTEMS
17 RANDOX LABORATORIES LTD.
18. ROCHE DIAGNOSTICS
19. SIEMENS AG
20. THERMO FISHER SCIENTIFIC INC.
